Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Here's Why Spark Therapeutics, Inc. Is Getting Hammered Today


Here's Why Spark Therapeutics, Inc. Is Getting Hammered Today

Shares of Spark Therapeutics, Inc. (NASDAQ: ONCE), a biotech developing gene therapies, fell hard this morning after the company reported hemophilia trial data that bodes well for rival BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Spark Therapeutics stock has fallen about 40% as of 11:01 a.m. EST on Monday. 

Spark's stock surged when SPK-8011 produced some encouraging data earlier this year. It's giving a lot of its gains back today after the company released data that suggests a potential competitor from BioMarin might have the upper hand from this point forward.

Image source: Getty Images.

Continue reading


Source: Fool.com

Spark Therapeutics Stock

€102.55
1.030%
Spark Therapeutics gained 1.030% today.

Like: 0
Share

Comments